ANOVA, analysis of variance
When the normal accumulation ofDHA (22:6n-3) in the retina and brain is limited during development by diets deficient in the n-3 fatty acid, a-linolenate, deficits in visual acuity (1) , abnormal retinal responses to light (2) (3) (4) (5) (6) , and impaired discrimination learning (7) (8) (9) occur in rats and primates. VLBW infants may also be at risk for inadequate accumulation of this fatty acid during development, not because of n-3-deficient diets, but because they miss the period of greatest intrauterine accretion (10) (11) (12) and frequently receive diets without DHA after birth (13) (14) (15) . RBC DHA declines over time in VLBW infants, and the decline is diminished by human milk feeding (16) , bolus administration of marine oil (17) , and formulas containing ultrasonically dispersed marine oil (1 8) . All of these feeding trials (1 6-18) were of short duration (4-8 wk) . To maintain phospholipid DHA after discharge from the hospital and, ultimately, to determine if DHA is conditionally essential for some aspects of normal development in VLBW infants, stable, commercially prepared control and marine oil-supplemented formulas were necessary. When these became available, the two studies reported here were designed.
In both studies, infants were randomly assigned to receive formulas identical to commercially available preterm and term formulas (control) or experimental formulas differing from the control formulas only in the addition of small amounts of marine oil. Both control and experimental formulas were packaged without a product name. The first 4-wk feeding trial was designed to test the effects of two concentrations of marine oil in formula to determine the best marine oil concentration to use in an extended feeding trial. The second study, the extended feeding trial, was designed to provide data about the long-term effects of feeding 0.3% EPA and 0.2% DHA from marine oil on RBC and plasma phospholipid DHA and EPA of VLBW infants. Additionally, we were interested in the qualitative and quantitative effects of extended marine oil feeding on phospholipid AA in these infants: Short-term feeding trials with marine oil supplementation (17, 18) have not consistently shown effects on phospholipid AA, but EPA and DHA in marine oil are known to reduce AA in membrane phospholipids. Extended marine oil feeding, coupled with the known declines in AA that occur after premature birth (I 6), could result in clinically significant declines in AA.
Finally, formulas fed in earlier trials (1 6-18) contained lower levels of LLA (0.6 to 2.0% of total fatty acids or 0.3 to 1.0% of energy) than are currently found in infant formula (3.0 to 5.0% of total fatty acids or 1.5 to 2.5% of energy). RBC DHA in VLBW infants fed formula with 1.0 to 1.35% of energy from LLA did not differ from that in infants fed human milk (19, 20) . Although this may have been due to the short duration of the studies (4 to 5 wk), it was suggested that >2.0% of total fatty acids (> 1 .O% of energy) from LLA would permit incorporation of DHA in VLBW infants equivalent to human milk (1 9). The extended feeding trial addresses the effects on AA, DHA, and EPA of long-term feeding of 5.0% LLA (2.5% of energy) with and without the inclusion of EPA and DHA (0.25% energy).
MATERIALS AND METHODS

Selection of Subjects.
Preterm infants (600-1270 g birth weight) were eligible for the acute feeding study (study 1) when they had tolerated preterm formulas at intakes >462 to 504 kJ (1 10-120 kcal)/kg/d for 5-7 d. Infants were on room air or receiving oxygen (by oxyhood but not by mechanical ventilation) at enrollment. Informed consent was obtained before enrollment according to a protocol approved by the Institutional Review Board of The University of Tennessee, Memphis. A total of 2 1 infants were enrolled and randomized to receive one of three formulas (Formulas A, B, and C). Four infants were lost from the study: Two infants assigned to formula A and one infant assigned to formula B for necrotizing enterocolitis and one infant assigned to formula C for group B streptococcus meningitis. Table 1 contains a description of infants by formula fed in study I. ANOVA by formula showed the groups to be statistically indistinguishable except in prior need for mechanical ventilation ( p < 0.04).
Infants enrolled for extended follow-up (study 2) weighed between 748 and 1398 g at birth and were eligible for the study when they were receiving >462 kJ (1 10 kcal)/kg/d of a formula designed for preterm infants. Although infants in this birth weight range are at high risk for medical complications, infants selected for this study had fewer and milder medical complications than the population from which they were selected. Infants could not require mechanical ventilation at the time of enrollment, although they could be receiving oxygen via oxyhood. Only three of 67 infants were diagnosed as having chronic lung disease or bronchopulmonary dysplasia, many fewer than would be expected in this birth weight range in our nursery. Infants with intraventricular/periventricular hemorrhage >grade 2, retinopathy of prematurity >stage 2, or necrotizing enterocolitis requiring surgical intervention were not eligible for this protocol. Infants who developed these complications after enrollment were replaced. Infants of mothers who used cocaine or other street drugs during the pregnancy were also excluded from enrollment. Criteria for enrollment were designed to eliminate factors known or suspected to adversely influence growth and/or development, two of the long-term outcome variables of this study.
Seventy-nine infants were enrolled and randomized to receive either control or marine oil-supplemented formula after obtaining parental consent according to an Institutional Review Boardapproved protocol. Infants were enrolled during a 2-y period Table 1 . Descriulion of infhnis between November 1987 and I989 and follow-up was completed in 1990. Ten of the 79 infants were replacements for infants who moved or failed to return for follow-up on or before 4 mo [57 wk postconception (noncompleters)]. Two additional infants from this group of 69 were excluded because they received soybased formula rather than the study formula between 4 and 6 mo. Table I includes a description of the 67 infants in the final study 2 group. Ventilator and total oxygen (h) were calculated by converting individual hours to log hours. The mean + SD (log hours) was calculated for each formula and reconverted to hours. All 67 infants (34 control/33 n-3 supplemented) completed follow-up through 4 mo. The data presented represent the following numbers of control and supplemented infants, respectively, at each age: 6 mo, 34 and 33; 9 mo, 31 and 31; 12 mo, 28 and 28. Experimental Design. Short-term study (study 1) . The objectives of this study were I ) to compare the acute effects of commercially prepared formulas containing two levels of marine oil on several 20-to 22-carbon n-6 and n-3 fatty acids in preterm infants and 2 ) to make this comparison with formulas containing 3.0% LLA (1.5% energy) instead of 0.6 to 2.0% LLA (approximately 0.3-1 .O% energy) as fed previously (16) (17) (18) . Accordingly, infants were fed one of three preterm formulas varying only in their quantity of eicosapentaenoate (EPA, 20:5n-3) and docosahexaenoate (DHA, 22:6n-3) for a period of 4 wk: Formula A did not contain marine oil and was free of EPA and DHA; formula B contained 0.3% EPA and 0.2% DHA from marine oil; and formula C contained 0.7% EPA and 0.4% DHA from marine oil ( Table 2 ). None of the formulas contained AA. Blood samples were obtained at enrollment and weekly for the next 4 wk for comparison of the effects of marine oil feeding on RBC and plasma phospholipid (PE, PC, and PS) and triglyceride fatty acids.
Long-term study (study 2) . The objective of this study was to determine the effects of extended feeding of marine oil-containing formula on phospholipid fatty acids (RBC, plasma), growth, visual acuity, and cognitive function throughout infancy. Results of the effects of the formulas on the fatty acid composition of RBC and plasma phospholipids are reported. We hoped to determine the effects of prolonged feeding and marine oil supplementation on RBC phospholipid DHA, EPA, and AA (g/100 g total fatty acids) and to observe the effects of time and marine oil supplementation on both the qualitative (g/100 g) and quantitative (mg/L) amounts of DHA, EPA, and AA of plasma phospholipids. Infants were randomized to receive either formula A or formula B during their hospitalization and were discharged from the hospital at approximately 1800 g. At discharge they received a formula designed for term infants without or with marine oil supplementation according to their original randomization (formula A-T or formula B-T) ( Table 2 ) until 79 wk postconception. Formula was provided free of charge in the quantities taken ad libitum by infants. Parents were counseled regularly throughout infancy to ensure that formula was truly studied (mean + SD, ranze)
Study 1 Study 2
Formula A Formula B Formula C Formula A and A-T Formula B and B-T (n = 6) (n = 6) (n = 5) (n = 34) (n = 33) fed ad libitum and not limited by the caretaker. Nutrition counseling included advice to limit intake of energy sources other than formula through the 57 wk appointment. Diet histories were obtained at each follow-up visit, with questions aimed at infants' typical intake of formula and other energy sources. Most infants received little but formula through 57 wk PCA; by 68 wk, all infants were consuming other foods but still consuming at least 24 ounces/d of their assigned formula (except one infant who was consuming 20 ounces/d). At 79 wk PCA, parents kept leftover formula and reported to us when it had been consumed. Infants continued to receive their designated formula for up to 4 wk beyond 79 wk PCA. Blood samples were obtained at enrollment and at regular intervals throughout infancy: term (38 + 2 wk PCA, mean + SD); 2 mo (48 + 2 wk PCA); 4 mo (57 f 2 wk PCA); 7 mo (68 f 2 wk PCA); 9 mo (79 + 2 wk PCA); and 12 mo (93 t 2 wk PCA) for the purpose of comparing phospholipid fatty acid profiles as affected by time and marine oil supplementation.
Analytical methods. Blood (1.5 mL) was removed from the antecubital or femoral vein and anticoagulated with lithium heparin. After the plasma was removed, the erythrocytes were washed three times with 0.15 M NaCl in 1 mM EDTA, resuspended in an equal volume of the saline-EDTA solution, and stored at -70 "C. Samples were stored less than 7 d before fatty acid analysis. Total lipids were extracted from plasma and erythrocytes according to Dodge and Phillips (2 1) with chromatography grade solvents and washed with 0.15 M KC1 according to Folch et al. (22) to remove nonlipid contaminants. PE, PS, and PC were separated on silica gel plates (10 x 10 cm, 0.25 mm; Analtech, Inc., Newark, DE) for 20 min in chloroform-methanolacetic acid-water (60:30:8.4:4.6, vol/vol/vol/vol), a modification of the solvent system of Zail and Pickering (23) and identified and recovered for methylation as described previously (17) . Butylated hydroxytoluene (50 mg/L) was added to the methanol in the eluting solvent. In study 1, the total lipid extract was spotted on a 10 (wide) x 20 (high) cm plate. Triglycerides were separated from total phospholipids (24) . The total phospholipids that remained at the origin were then separated as described above by a modification of the solvent system of Zail and Pickering (23) . Fatty acids in phospholipids and triglycerides were methylated according to Morrison and Smith (25) in an oxygen-free atmosphere.
Methylated fatty acids from both phospholipids and triglycerides were extracted with pentane, the solvent vaporized under nitrogen, and the samples dissolved in 10 FL dichloromethane. The fatty acid methyl esters were injected onto a 30 m x 0.25 mm open tubule column with a stationary liquid phase (SP-2330; Supelco, Inc., Bellefonte, PA) installed in a Varian 3300 gas chromatograph programmed for column, injector, and detector temperatures of 175, 2 10 and 220°C. Helium was used as the carrier gas. The column temperature was held constant for 5 min after injection then advanced at 2"C/min to 195°C and held constant for an additional 5 min. Individual peaks were integrated and identified automatically with a programmable Varian 4290 recorder/integrator. Identification of individual fatty acids was made by comparison to authentic standards and by loglinear plots of retention times of authentic standards plotted after isothermal gas liquid chromatography separations. A biologic mixture of fatty acids containing the fatty acids of interest was analyzed daily (PUFA 1; Supelco, Inc.), and other quantitative standards (NHI-C, NHI-F, NHI-C, and NHI-D; Supelco, Inc.) were analyzed periodically to check column integrity.
To determine quantitatively the amount of each fatty acid in plasma phospholipids and triglycerides, the procedures for lipid extraction, thin layer chromatography, methylation, and gas liquid chromatography were used as detailed previously but with careful attention to quantitative technique: Total lipids were extracted from 0.3 mL plasma, the extract reconstituted in 0.3 mL dichloromethane, and 0.15 mL of the extract spotted on the silica gel plate. After separation of triglycerides, PE, and PC, the bands were quantitatively removed to tubes containing heptadecanoic acid (17:O) as an internal standard during the methylation, reextraction, and chromatographic separation of individual fatty acids by gas liquid chromatography. For the purposes of this study, total plasma phospholipid (Fig. 3) was determined by combining the individual quantitative analyses (mg/L) of fatty acids from plasma PE and PC. These two phospholipids accounted for >95.0% of total plasma phospholipids.
Statistical methods. In study I, plasma and RBC PE and PC, RBC PS, and plasma triglycerides were analyzed for the effects of marine oil supplementation and time (data for RBC PS are not presented) and the interaction of time and supplementation using a repeated measures ANOVA (Tables 3 and 4 ). The effects of marine oil supplementation, time, and their interaction on RBC and plasma PE (Fig. 1) and PC (Fig. 2) AA, EPA, and DHA (g/100 g total fatty acids) were determined by ANOVA. In addition, the effects of time and marine oil supplementation on the concentration of total plasma phospholipid AA and DHA (mg/L) were determined by ANOVA. Analyses were completed using a Macintosh IIcx and StatView I1 software (Abacus Concepts, Inc., Berkeley, CA) (26) and software from SAS Institute, Inc. (27) on the mainframe computer at the University of Tennessee, Memphis. In both studies, preplanned comparisons between diet groups and tissues were made using Fisher's least squares difference (28) . The effects of packed RBC and several other variables [birth weight, age at enrollment, i.v. lipids (mL), and birth order] on RBC and plasma phospholipid AA and DHA at enrollment were studied by multiple regression. Multiple regression analyses for AA and DHA at term also included packed RBC (mL) administered after enrollment and formula (control or marine oil supplemented). Only 15 infants received RBC after enrollment.
RESULTS
Acute Effects of Marine Oil Supplementation on DHA, EPA, and AA (Study I).
There was an interaction between time and marine oil supplementation on RBC and plasma phospholipid DHA. DHA either declined (plasma and RBC PE and PS) or was unchanged (plasma and RBC PC) in unsupplemented infants receiving 3.0% LLA, whereas it increased in marine oil-supplemented infants (Table 3) . Data for PS are not shown because changes were essentially identical to those shown for PE. The mean level of RBC DHA seen in marine oil-supplemented infants was higher than reported after long periods of human milk feeding (15, 16), but not higher than found in cord blood (16) . The absolute amount of DHA in plasma phospholipids (mg/L) tended to decline in controls and rise in marine oilsupplemented infants over time, although this did not always reach statistical significance (Table 4) . EPA typically accounted for only 0.4 to 0.7% of total fatty acids in plasma and RBC phospholipids of control infants. EPA increased 2-to 8-fold in individual lipid classes when the marine oil formulas containing EPA and DHA were fed ( Table 3) . As might have been expected, a greater increase in EPA occurred in infants fed the higher amount of EPA (formula C). EPA concentrations did not appear to plateau during 4 wk of feeding. Most EPA was found in plasma PC, and there was a highly significant increase in PC EPA (mg/L) with marine oil supplementation. EPA (mg/L) also increased significantly in plasma PE and triglycerides (Table 4) .
Plasma PE and PC AA (g/100 g total fatty acids) decreased with time and marine oil supplen~entation (ANOVA, Table 3 ), but the absolute concentration of AA in plasma (mg/L) decreased only as a result of time (ANOVA, Table 4 ). RBC PE and PC AA decreased with time, but further effects of diet were not seen.
Other fatty acids affected by time and/or marine oil supplementation but for which data are not shown included: I ) docosapentaenoate (22:5n-3) from LLA, which increased minimally but significantly as a result of both marine oil supplementation and time, and 2) docosapentaenoate (22:5n-6) from LOA (1 8:2n-6), which decreased slightly as a result of both supplementation and time. In general, docosaquatraenoate (22:4n-6) was unaffected by time and diet but did increase significantly in RBC PS of control infants compared with those supplemented with marine oil. LOA, LLA, and eicosadienoate (20:2n-6) tended to be increased, and the A6-desaturation products of LOA (1 8:3n-6 and 20:3n-6) tended to be decreased in supplemented compared with control infants.
Long-Term Marine Oil Supplementation: RBC and Plasma Fatty Acids. Changes in AA, EPA, and DHA (g/100 g totulfatiy acids). Effects of time, marine oil supplementation, and interactions between time and supplementation were noted for RBC and plasma DHA. Both diet groups had similar PE and plasma PC DHA at enrollment (33 + 2 wk PCA). Subsequently, higher amounts of DHA were observed in PE and PC of marine oilsupplemented compared with control infants at all times during the feeding portion of the study (38 to 79 wk PCA) (Figs. 1 and  2) . Furthermore, DHA remained significantly higher in supplemented infants compared with controls even several months after the feeding portion of the study was completed (93 wk PCA) and infants were consuming a mixed diet with cows' milk.
The patterns of DHA response in the two phospholipid classes (PE and PC) differed. PE DHA decreased significantly in controls and was maintained (RBC) or increased (plasma) with marine oil supplementation ( Fig. 1 C and F) . PC DHA remained low and unchanged in controls but rose gradually in both RBC and plasma of marine oil-supplemented infants, reaching a plateau between 48 and 79 wk PCA ( Fig. 2C and F) . RBC and plasma PC DHA declined after the feeding portion of the study but were still higher than controls at 93 wk PCA. RBC and plasma PE (Fig. 1A and D) and PC ( Fig. 2A and D ) AA were significantly affected by time and marine oil supplementation (ANOVA). The largest decrease in plasma phospholipid AA and RBC PC AA occurred between enrollment (33 + 2 wk PCA) and term (38 + 2 wk PCA). AA in marine oilsupplemented compared with control infants was further reduced in RBC and plasma PE (Fig. I) and PC (Fig. 2) by term. Marine oil-supplemented infants continued to have lower plasma AA than controls throughout infancy (93 wk) (Figs. 1 and 2) , even though no infant received marine oil supplementation after 83 wk PCA. Plasma AA began to increase gradually after 57 wk PCA. A more gradual increase in AA late in infancy occurred in infants fed the marine oil-containing formula compared with their controls. RBC PE AA also decreased over time and reached lower levels in marine oil-supplemented infants than in controls. The decreases in RBC PE AA were much more gradual than in plasma phospholipids (PE and PC) and in RBC PC, however, and reached a nadir later in marine oil-supplemented infants (-68 wk PCA). AA returned to enrollment levels (Figs. 1A and D, 2A and D, and 3A) only after most infants were eating a mixed diet and drinking whole cows' milk instead of formula.
RBC and plasma PE EPA in control infants remained low throughout the period of study, rising slightly at 93 wk PCA ( Fig.  1 B and E) . In PC, EPA declined between enrollment and term, remained low throughout infancy, and also increased slightly at 93 wk. In contrast, EPA increased over time in RBC and plasma phospholipids of marine oil-supplemented infants, reaching a maximum at 57 wk in PC (Fig. 2B and E) and 68 wk in PE ( Fig.  1 B and E) .
Because preterm infants have quite variable neonatal/perinatal histories and exposures to factors that could influence phospholipid fatty acids (such as i.v. lipids and packed RBC), we determined the extent to which these factors were related to the AA and DHA at enrollment and term (Table 5 ). Age at enrollment and i.v. lipids (Intralipid; KabiVitrum Inc., Clayton, NC) were the factors most likely to influence AA and DHA at enrollment. Age at enrollment was associated with lower AA and DHA. Intralipid was associated with lower AA. At term, n-3 supplementation accounted for 40 to 55% of the variance in plasma and RBC DHA (positively related) and 10 to 2 1 % of the variance in AA (negatively related). Minor effects of packed RBC were seen on RBC PE DHA at term, with the quantity before enrollment having a small negative effect and the quantity after enrollment a small positive effect.
Changes in AA and DNA (mg/L). The effects of time and marine oil supplementation on the quantity of AA and DHA in plasma phospholipids are shown in Figure 3A and B. Time and marine oil supplementation significantly affected both fatty acids ( p < 0.001). When infants fed the control preterm and term formulas (formula A followed by formula A-T) were compared with those fed a low level of marine oil supplementation (formula B followed by formula B-T), those receiving marine oil had significantly more plasma phospholipid DHA at all times after enrollment (Fig. 3B) . Plasma DHA in supplemented infants continued to rise over a 2-mo period and then remained high throughout the period of marine oil supplementation (to 79 wk postconception) (Fig. 3B) . DHA was still elevated in experimen- Fisher's least squares difference (28) .
tal compared with control infants at 93 wk PCA, 2-3 mo after 79 wk PCA). The mean concentration of AA did begin to increase marine oil was removed from the diet. gradually during the last half of infancy, but the higher concenPlasma phospholipid AA (mg/L) decreased significantly be-trations of AA seen at enrollment were not reached again until tween enrollment and term regardless of the formula fed (Fig. 93 wk PCA. Beginning at term and continuing through 79 wk 3A). Furthermore, the concentration of AA in plasma remained PCA, the quantity ofplasma AA was significantly lower in infants lower than enrollment throughout the feeding period (through receiving the marine oil supplement compared with controls. Because the gradual rise in AA during the study period did not DISCUSSION occur until very late in supplemented infants and was of smaller magnitude than seen in controls, the difference in AA between These studies demonstrate conclusively that even large groups became larger over time.
amounts of LLA do not prevent declines in RBC and plasma phospholipid DHA in VLBW infants. Moreover, RBC PE DHA levels at term were below those typically seen in infants born at term (16) , suggesting that DHA status was less than optimal throughout the last trimester. At enrollment, plasma phospholipid DHA was 2.0% compared with 2.5% reported for n-3 deficient monkeys at birth (I), suggesting that DHA status of VLBW infants is at least as poor as n-3 deficient monkeys at birth. Unlike monkeys deprived of LLA, however, these preterm infants fed LLA did not experience continued postnatal declines in plasma phospholipid DHA to extremely low levels, evidence that LLA is converted to DHA to some degree. Declines in RBC DHA followed those in plasma phospholipids, but the two compartments did equilibrate eventually. The lower levels of DHA found in RBC PE ofthese infants compared with those previously reported in cord blood (16) and after human milk feeding (15, 16) suggest that VLBW infants do not generate DHA from LLA at optimal rates. Preformed 20-and 22-carbon fatty acids accumulate in membranes more avidly than their 18-carbon precursors (29) . During marine oil supplementation, RBC PE DHA plateaued in these infants at 7.0 to 8.0% of total fatty acids; i.e. in the range found in RBC of cord blood (16) and in breast-fed term infants (15) and twice as high as in controls fed 5.0% LLA. Moreover, those fed the experimental, marine oil-supplemented formula to 57 wk postconception had improved visual acuity [Teller acuity card procedure (30)] compared with control infants (3 I), suggesting that retinallneural function was optimized by marine oil supplementation. Uauy et al. (32) also reported improved visual evoked potential acuity at 57 wk in VLBW infants fed different marine oil-supplemented and control formulas to 57 wk.
Infants did not receive dietary AA in the first 6 mo of life, and RBC and phospholipid AA declined continuously during this period. The declines in plasma phospholipid AA were consistent with reduced AA synthesis because decreases in RBC phosphlipid AA occurred after those in plasma phospholipids. The decline in AA over time could be due in part to consumption of Iarge amounts of LOA in formula, inasmuch as plasma phospholipid AA was shown to decrease in adults (33) and term infants (34) consuming >5.0-7.0% of energy from LOA. However, identical amounts of AA were found in RBC phospholipids of term infants fed formulas with 7.0 and 22.0% of energy from LOA for many months (15) , suggesting that some mechanism other than high LOA intake or in concert with high LOA intakes is responsible for the decline in AA seen in these preterm infants.
Extended feeding of marine oil-supplemented formula reduced RBC and plasma phospholipid AA over and above the reductions seen with time. EPA in phospholipids rose during the same period. Whether lower RBC and plasma AA in marine oil-fed infants reflect a further seduction in AA synthesis or merely the substitution of dietary EPA for AA in phospholipids cannot be determined from these data. During the acute feeding trial, plasma phospholipid AA was reduced significantly. We did not find any effect of marine oil on RBC phospholipid AA, but the reduction in plasma phospholipid AA is evidence that decreases would have occurred had feeding of marine oil-supplemented preterm formula been continued.
AA rose in the second half of infancy, but the increase in plasma phospholipid AA did not appear to be related to maturation of elongation/desaturation of 18-carbon fatty acids, inasmuch as phospholipid DHA did not increase at any time during infancy. The slight upward trend in plasma phospholipid AA beginning around 7 mo coincided with the inclusion of energy from eggs and meat, both dietary sources of AA. We have reported that the number of servings of eggs and meat positively influenced plasma phospholipid AA, accounting for 10.0 and 15.0% of the variance in AA at 79 and 93 wk, respectively (35) .
We anticipated that feeding of very long chain n-3 fatty acids would diminish AA status to some degree. However, our early, extended studies of term infants (1 5) did not lead us to anticipate a fall in RBC and plasma AA in the absence of marine oil supplementation or an association between diminished AA status and poorer growth (36, 37) and cognition (38) . Although we ( 3 1) and others (32) have reported associated improvements in visual acuity with marine oil supplementation of formula, the optimal period of n-3 supplementation is not known. Studies in which visual acuity has been improved have involved marine oil supplementation until at least 57 wk postconception (3 1, 32 ). These studies demonstrate that supplementation of this duration with low levels of EPA and DHA (0.25% of energy) decreases RBC and plasma phospholipid AA. Shorter feeding trials, DHA-containing formulas free of EPA, and formulas including AA need to be considered. These studies will need to monitor biochemistry, growth, cognition, and visual or retinal development. The ultimate goal should be to improve DHA status without creating potentially more serious deficits in AA status.
